The frequency of factor V G1691A (Leiden) mutation in the healthy Kazakh population by Hakkı Taştan
352 Letter to the Editor  
The frequency of factor V G1691A (Leiden) 
mutation in the healthy Kazakh population  
Sağlıklı Kazak popülasyonunda faktör V G1691A (Leiden) mutasyon sıklığı
Hakkı Taştan
Department of Biology, Faculty of Science, Gazi University, Ankara, Turkey
Address for Correspondence: Assoc. Prof. Hakkı Taştan, Department of Biology, Faculty of Science, Gazi University, Ankara, Turkey
Phone: +90 312 202 13 98 E-mail: hakkitastan@gazi.edu.tr
doi:10.5152/tjh.2011.96
To the Editor, 
Factor V G1691A (Leiden) (FVL) is an autosomal 
dominant mutation that causes activated protein C 
(APC) resistance, which results in hypercoagulation 
disorders [1]. The mutation is unevenly distributed, 
ranging from non-existent in Africa, America, Asia, 
and Australia, to an incidence as high as 15% in some 
regions of Europe [2,3]. 
Kazakhs  emerged  as  a  unique  ethno-linguistic 
group during the 13th century AD [4], after invading 
the region that is now modern Kazakhstan. At that 
time, many tribes of Turkish and Mongolian origin 
inhabited the region [4,5]. The Kazakh ethnic identi-
ty,  which  was  distinguishable  by  its  distinctive 
Kipchak  Turkish  dialect,  emerged  in  this  complex 
sociocultural environment [4]; however, the Kazakhs 
did not form a unified Khanate like other Turkish-
speaking groups. Instead, during the 15th and 16th 
centuries they subdivided into 3 major tribal confed-
erations: the Greater, Middle, and Lesser (Hordes) 
[4,6]. This division likely occurred via already existing 
tribal lines, and marked a political, as well as geo-
graphical split.
The frequency of FVL in Europe is 3%-10%. It is 
rare in East and Southeast Asia,  occurs with a 12%     
frequency  in  such  neighboring  countries  as 
Azerbaijan and Kyrgyzstan [7-9], and has a frequen-
cy  of  3.1%  in  western  Iran  [10].  The  best  of  my 
knowledge  the  frequency  of  FVL  in  the  Kazakh 
population  has  not  been  reported.  The  present 
study  included  69  healthy  Kazakh  individuals.  All 
the participants provided informed consent. Blood 
samples were collected into EDTA-containing tubes 
and then DNA was extracted from peripheral blood 
leukocytes.  FVL  analysis  was  performed  via  real-
time PCR (RT-PCR), as previously described [11]. In 
all, 3 (4.3%) of the 69 participants were heterozy-
gous for FVL and the frequency of FVL was 0.02% 
among the Kazakh population. The data obtained 
show that the frequency of FVL in Kazakhs is similar 
to that in the general Caucasian population.
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